Tag Archive for LifeVantage

LifeVantage Revenue Q1 2025 Up 21.1% To $58.4 Million

LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025.
Third Quarter Fiscal 2025 Summary*:

Revenue was $58.4 million, an increase of 21.1% from the prior year period.
Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximately 22.1%;
Revenue in the Americas increased 29.5%, and revenue in Asia/Pacific & Europe decreased 7.2%.
Excluding the negative impact of foreign currency fluctuations, third quarter revenue in Asia/Pacific & Europe decreased approximately 4.7%;
Net income per diluted share was $0.26, versus $0.13 per diluted share a year ago;
Adjusted earnings per diluted share was $0.26, compared to $0.21 a year ago; and
Adjusted EBITDA was $6.4 million compared to $5.1 million a year ago.

* All comparisons are on a year over year basis and compare the third quarter of fiscal 2025 to the third quarter of fiscal 2024, unless otherwise noted.
Steve Fife, President and CEO of LifeVantage said:

“Third quarter results were strong with revenues up 21% year-over-year to $58.4 million, reflecting robust demand for our MindBody GLP-1 System™. We also delivered another quarter of improving profitability including a 210 basis point improvement

Read more...

LifeVantage Welcomes Thousands From Around the World at Global Convention

Attended By Over 2,000 Independent Consultants, LifeVantage Global Convention Hosted in Salt Lake City, Utah, Empowers Consultants to ‘Go Further’ With Exclusive Trainings, Product Announcements, and New Incentives to Drive Growth. 
LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the successful conclusion of their annual Global Convention, held April 24-26, 2025, in Salt Lake City, Utah.
Thousands of independent LifeVantage Consultants from around the world gathered at the Salt Palace Convention Center to participate in the multi-day event. Attendees heard from a variety of LifeVantage executives and speakers on key business updates, exciting product announcements, exclusive business and compensation plan trainings, and initiatives designed to help Consultants “Go Further” with their LifeVantage business.
Steve Fife, President and CEO of LifeVantage said.

“Our ‘Drive ERA’ theme, launched at Global Kickoff earlier this year, continued in full force at Convention, We are so proud of what we offer the world. This Convention was the rallying cry to get loud about what we do better than anyone else and the opportunity to deliver meaningful side income to people willing to work alongside our incredible leaders. The excitement and unity among our field and corporate teams was truly inspiring, and it’s that shared energy

Read more...

LifeVantage Launches MB System™ in International Markets

LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is extending its groundbreaking MindBody GLP-1 System™ to international markets.
This expansion comes after a 49% year-over-year increase in fiscal Q2 revenue ending December 31, 2024, in the U.S., largely driven by the system’s success, and clinical data on that formula reinforcing its effectiveness in supporting GLP-1 production.
The MB System™, as the product is known internationally, launched on March 15 for both LifeVantage Consultants and Customers in Japan. On the same date, it became available exclusively to Consultants in Australia, New Zealand, Europe, UK, Mexico, and Thailand; Customers in these regions gain access starting April 25.
The MB System™ is designed to naturally activate the body’s own GLP-1 production, providing a range of long-term health benefits that expand to weight management and beyond.*

“Consumers worldwide are seeking sustainable health solutions that go beyond short-term, unsustainable weight management. The MB System™ works harmoniously with the body, empowering individuals to naturally enhance their metabolic health in alignment with their lifestyle and wellness objectives,”*

shared Steve Fife, President and CEO of LifeVantage.

Meeting a Growing Global Demand
Interest in GLP-1 and metabolic health is rising worldwide. The global GLP-1 pharmaceutical market

Read more...

LifeVantage Expands To The Philippines, Taiwan, Hong Kong And Singapore

LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the successful launch of the Evolve Compensation Plan and other LV360 initiatives into the

Philippines
Taiwan
Hong Kong
Singapore

The transition went into effect in these markets on March 1, 2025, after the successful launch of LV360 into Canada, Mexico, and Europe last February, and the launch in the US, Australia, New Zealand and Japan in March 2023.
Steve Fife, President and CEO of LifeVantage said:
“When we launched the LV360 and the Evolve Compensation Plan two years ago, we did so with a clear vision of where the direct sales industry was headed. That transformation has proven invaluable for our independent Consultants, equipping them for the world we live in today. As we enter this next phase, we’re proud to bring this transformation to more international markets and empower Consultants with the tools to help their businesses thrive.”
The Evolve Compensation Plan is designed to reward Consultants generously, providing opportunities for multiple income streams tied to business building and product sales initiatives with a clear path to success. It supports both entrepreneurs focused on sharing and selling products within their networks and those looking to build strong, collaborative teams.
With early income bonuses that encourage smart business

Read more...

Renee Parker Featured Recommended Distributor For LifeVantage

A beacon of success in the network marketing industry, Renee Parker has admirably secured her position as a Featured Recommended Distributor.
She stands as an inspiration through her association with LifeVantage, a world-renowned network marketing company. For more insights into her professional strides, you can reach out on her Facebook page. This narrative explores her achievements, telling a tale of perseverance and dedication, without offering any guarantees or promoting commercial gain.
Renee Parker has achieved remarkable success as a recommended distributor at LifeVantage, a prominent network marketing company. Her leadership and motivation have contributed greatly to her success. Renee Parker is a resident of Valdosta, Georgia, USA, and studied at the Valdosta State University.
She is known for her leadership qualities, confidence, and her ability to inspire respect among her team and explain the power of a compensation plan effectively.
Here’s what people are writing about working with Renee Parker:
After thorough analysis of the Business for Home reviews for Renee Parker, it can be concluded that reviewers shared many positive sentiments about her work as a distributor. Their remarks evidenced an appreciation for her professionalism, dedication, and effectiveness.
Reviewer Serina Glasscock said

“I have been working with Renee for a little while now and I can

Read more...

LifeVantage Q4 2024 Revenue Up 31.3% To $67.8 Million

LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its second fiscal quarter ended December 31, 2024.
Second Quarter Fiscal 2025 Summary*:

Revenue of $67.8 million, an increase of 31.3% from the prior year period. Excluding the negative impact of foreign currency fluctuations, second quarter revenue was up approximately 31.9%;
Revenue in the Americas increased 46.3%, and revenue in Asia/Pacific & Europe decreased 15.5%. Excluding the negative impact of foreign currency fluctuations, second quarter revenue in Asia/Pacific & Europe decreased approximately 13.7%;
Net income per diluted share was $0.19, versus a loss of $0.05 per diluted share a year ago;
Adjusted earnings per diluted share was $0.22, compared to $0.10 a year ago; and
Adjusted EBITDA was $6.5 million compared to $3.1 million a year ago.

* All comparisons are on a year over year basis and compare the second quarter of fiscal 2025 to the second quarter of fiscal 2024, unless otherwise noted.
“Second quarter results were outstanding with year-over-year revenue growth exceeding 31% to a record $67.8 million, driven by tremendous demand for the MindBody GLP-1 System™ we introduced into the U.S. market in October,”
said Steve Fife, President and CEO of LifeVantage.
“We also continued to deliver strong profitability metrics and growth in Active Accounts, which was equally impressive, up 25% sequentially in the Americas, as the number of enrollments

Read more...

LifeVantage Q2 Revenue Up 31% To $67.5 Million

LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced preliminary revenue results for the second quarter ended December 31, 2024, and raised its fiscal 2025 revenue guidance.
Preliminary Second Quarter Fiscal 2025 Highlights:

Revenue of approximately $67.5 million, an increase of 31% from the prior year period, and up 43% sequentially from the first fiscal quarter

Active Account growth in the Americas of 22.7% in comparison to the prior year period, and up 25.4% sequentially from the first fiscal quarter

Active Account growth of 12.1% globally in comparison to the prior year period, and up 18.5% sequentially from the first fiscal quarter

Fiscal 2025 Guidance:

The Company now expects revenue in the range of $235 million to $245 million in fiscal 2025 compared to prior revenue guidance of $200 million to $210 million

“Second quarter revenue results were exceptional, reflecting strong sales of the MindBody GLP-1 System™ we launched in October in the United States along with outstanding execution by our team to quickly ramp supply chain and fulfillment capacity to meet the robust demand,”

said Steve Fife, President and CEO of LifeVantage.

“We also saw significant growth in Active Accounts driven by the highest number

Read more...

LifeVantage Q1 Revenue Down 7.7% To $47.2 Million

LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2024.
First Quarter Fiscal 2025 Summary*:

Revenue of $47.2 million, a decrease of 8.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, first quarter revenue was down approximately 7.7%;
Revenue in the Americas decreased 4.2%, and revenue in Asia/Pacific & Europe decreased 19.7%. Excluding the negative impact of foreign currency fluctuations, first quarter revenue in Asia/Pacific & Europe decreased approximately 18.7%;
Net income per diluted share was $0.14, versus $0.05 per diluted share a year ago;
Adjusted earnings per diluted share was $0.15, compared to $0.13 a year ago; and
Adjusted EBITDA was $4.4 million compared to $4.0 million a year ago.

* All comparisons are on a year over year basis and compare the first quarter of fiscal 2025 to the first quarter of fiscal 2024, unless otherwise noted.

“It’s an incredible time to be at LifeVantage as we just launched the MindBody GLP-1 System™, an amazing innovation targeting consumers searching for an effective, sustainable weight management solution. This product, launched on October 11th, significantly expands our total addressable market and the

Read more...

LifeVantage Completes Successful Human Clinical Trial With New GLP-1 System

LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, has completed its randomized, 12-week human clinical trial evaluating the efficacy of its innovative GLP-1 system for weight management. The study was conducted to explore the system’s potential to activate GLP-1 in users and support their health goals. * †
The clinical trial, which began in mid-June 2024, involved 60 participants and was designed to assess the impact the innovative two-product system has on weight management, food cravings, and overall well-being, among other factors. * †
Participants were divided into three groups to evaluate the system’s effects under different conditions, comparing the product system alone, the product system combined with diet and exercise guidance, and a control group, over the course of the three-month period.

“We are thrilled to have completed this key phase of our research and for the results we are seeing with these products,”

said Lisa Barnes, Vice President of Research, Development & Regulatory at LifeVantage.

“The data from this human clinical shows a remarkable ability of our unique two-product system to address weight management challenges through the natural activation of the health-supporting hormone, GLP-1. We remain confident that

Read more...

LifeVantage Annual Revenue Down 6.2% To $200.2 Million

LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2024.
Fourth Quarter Fiscal 2024 Summary*:

Revenue of $48.9 million, a decrease of 9.8% from the prior year period. Excluding the negative impact of foreign currency fluctuations, fourth quarter revenue was down approximately 8.0%;
Revenue in the Americas decreased 4.1% and revenue in Asia/Pacific & Europe decreased 25.2%.
Excluding the negative impact of foreign currency fluctuations, fourth quarter revenue in Asia/Pacific & Europe decreased 18.6%;
Net income per diluted share was $0.10, versus $0.15 per diluted share a year ago;
Adjusted earnings per diluted share were $0.14, compared to $0.17 a year ago; and
Adjusted EBITDA of $4.8 million was flat compared to a year ago.

*All comparisons are on a year over year basis and compare the fourth quarter of fiscal 2024 to the fourth quarter of fiscal 2023, unless otherwise noted.
Fiscal Year 2024 Summary**:

Revenue of $200.2 million, a decrease of 6.2%.
Excluding the negative impact of foreign currency fluctuations, fiscal year 2024 revenue was down approximately 5.2%;
Revenue in the Americas decreased 1.6%, and revenue in Asia/Pacific & Europe decreased 18.6%.
Excluding

Read more...